Display options
Cite
Yager EJ, Kim IJ, Freeman ML, et al. Differential impact of ageing on cellular and humoral immunity to a persistent murine gamma-herpesvirus. Immun Ageing. 2010;7:3doi: 10.1186/1742-4933-7-3.
Yager, E. J., Kim, I. J., Freeman, M. L., Lanzer, K. G., Burkum, C. E., Cookenham, T., Woodland, D. L., & Blackman, M. A. (2010). Differential impact of ageing on cellular and humoral immunity to a persistent murine gamma-herpesvirus. Immunity & ageing : I & A, 73. https://doi.org/10.1186/1742-4933-7-3
Yager, Eric J, et al. "Differential impact of ageing on cellular and humoral immunity to a persistent murine gamma-herpesvirus." Immunity & ageing : I & A vol. 7 (2010): 3. doi: https://doi.org/10.1186/1742-4933-7-3
Yager EJ, Kim IJ, Freeman ML, Lanzer KG, Burkum CE, Cookenham T, Woodland DL, Blackman MA. Differential impact of ageing on cellular and humoral immunity to a persistent murine gamma-herpesvirus. Immun Ageing. 2010 Feb 02;7:3. doi: 10.1186/1742-4933-7-3. PMID: 20181071; PMCID: PMC2843645.
Copy Download .nbib Format: NLM
Share it on

Immun Ageing. 2010 Feb 02;7:3. doi: 10.1186/1742-4933-7-3.

Differential impact of ageing on cellular and humoral immunity to a persistent murine gamma-herpesvirus.

Immunity & ageing : I & A

Eric J Yager, In-Jeong Kim, Michael L Freeman, Kathleen G Lanzer, Claire E Burkum, Tres Cookenham, David L Woodland, Marcia A Blackman

Affiliations

  1. Trudeau Institute, 154 Algonquin Ave, Saranac Lake, NY 12983, USA.

PMID: 20181071 PMCID: PMC2843645 DOI: 10.1186/1742-4933-7-3

Abstract

BACKGROUND: Oncogenic gamma-herpesviruses establish life-long infections in their hosts and control of these latent infections is dependent on continual immune surveillance. Immune function declines with age, raising the possibility that immune control of gamma-herpesvirus infection becomes compromised with increasing age, allowing viral reactivation and/or increased latent load, both of which are associated with the development of malignancies.

RESULTS: In this study, we use the experimental mouse gamma-herpesvirus model, gammaHV68, to investigate viral immunity in aged mice. We found no evidence of viral recrudescence or increased latent load in aged latently-infected mice, suggesting that effective immune control of gamma-herpesvirus infection remains intact with ageing. As both cellular and humoral immunity have been implicated in host control of gammaHV68 latency, we independently examined the impact of ageing on gammaHV68-specific CD8 T cell function and antibody responses. Virus-specific CD8 T cell numbers and cytolytic function were not profoundly diminished with age. In contrast, whereas ELISA titers of virus-specific IgG were maintained over time, there was a progressive decline in neutralizing activity. In addition, although aged mice were able to control de novo acute infection with only slightly delayed viral clearance, serum titers of neutralizing antibody were reduced in aged mice as compared to young mice.

CONCLUSION: Although there is no obvious loss of immune control of latent virus, these data indicate that ageing has differential impacts on anti-viral cellular and humoral immune protection during persistent gammaHV68 infection. This observation has potential relevance for understanding gamma-herpesvirus immune control during disease-associated or therapeutic immunosuppression.

References

  1. J Virol. 2004 Mar;78(5):2255-64 - PubMed
  2. J Virol. 1997 Aug;71(8):5894-904 - PubMed
  3. J Virol. 1998 Feb;72(2):943-9 - PubMed
  4. J Virol. 1995 Dec;69(12):7416-22 - PubMed
  5. J Immunol. 2000 Feb 15;164(4):1820-8 - PubMed
  6. Science. 2003 Apr 11;300(5617):337-9 - PubMed
  7. Proc Soc Exp Biol Med. 1985 Jul;179(3):352-5 - PubMed
  8. Nat Med. 2003 Sep;9(9):1131-7 - PubMed
  9. Blood. 1994 Aug 1;84(3):972-84 - PubMed
  10. J Virol. 2001 Sep;75(17):8283-8 - PubMed
  11. J Infect Dis. 2004 Jun 1;189(11):2016-22 - PubMed
  12. J Immunol. 2003 Nov 15;171(10):4969-73 - PubMed
  13. Curr Opin Immunol. 2007 Jun;19(3):315-9 - PubMed
  14. Cell Immunol. 1992 Oct 15;144(2):332-46 - PubMed
  15. Science. 1996 Apr 5;272(5258):54-60 - PubMed
  16. N Engl J Med. 1993 May 6;328(18):1317-21 - PubMed
  17. J Exp Med. 1996 Nov 1;184(5):1891-900 - PubMed
  18. J Virol. 1994 Sep;68(9):6083-6 - PubMed
  19. Pathol Res Pract. 2008;204(4):267-72 - PubMed
  20. Vaccine. 2000 Feb 25;18(16):1649-53 - PubMed
  21. J Infect Dis. 1986 Aug;154(2):245-56 - PubMed
  22. J Immunol. 1995 Oct 1;155(7):3377-84 - PubMed
  23. J Virol. 1999 Jul;73(7):6006-14 - PubMed
  24. J Exp Med. 2000 Oct 2;192(7):943-52 - PubMed
  25. J Exp Med. 2005 Jul 4;202(1):123-33 - PubMed
  26. Mech Ageing Dev. 2005 Jun-Jul;126(6-7):822-5 - PubMed
  27. Hum Pathol. 1994 Jul;25(7):638-43 - PubMed
  28. J Gen Virol. 1992 Dec;73 ( Pt 12):3275-9 - PubMed
  29. J Exp Med. 1965 Jul 1;122:41-58 - PubMed
  30. Blood. 1994 May 1;83(9):2715-22 - PubMed
  31. Cancer Sci. 2008 Jun;99(6):1085-91 - PubMed
  32. Immunity. 2006 Jun;24(6):663-666 - PubMed
  33. Acta Microbiol Immunol Hung. 1997;44(2):133-40 - PubMed
  34. Clin Cancer Res. 2007 Sep 1;13(17):5124-32 - PubMed
  35. J Immunol. 2006 Jul 1;177(1):450-8 - PubMed
  36. Am J Surg Pathol. 2003 Jan;27(1):16-26 - PubMed
  37. J Infect Dis. 1996 Nov;174 Suppl 3:S306-9 - PubMed
  38. J Immunol. 2005 Apr 15;174(8):4972-8 - PubMed
  39. J Exp Med. 2002 Apr 1;195(7):F29-32 - PubMed
  40. J Immunol. 2000 Jul 15;165(2):1074-81 - PubMed
  41. J Immunol. 2007 Sep 15;179(6):3535-42 - PubMed
  42. Immunology. 1987 Apr;60(4):485-9 - PubMed
  43. J Exp Med. 1976 Oct 1;144(4):1037-48 - PubMed
  44. Virology. 2006 Sep 15;353(1):210-9 - PubMed
  45. Immunol Rev. 1997 Dec;160:9-18 - PubMed
  46. Immunol Rev. 2005 Jun;205:5-6 - PubMed
  47. Immunol Rev. 2005 Jun;205:285-96 - PubMed
  48. J Virol. 2002 Nov;76(22):11460-8 - PubMed
  49. Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 - PubMed
  50. Immunol Rev. 2006 Jun;211:146-53 - PubMed
  51. J Virol. 1999 Jun;73(6):4651-61 - PubMed
  52. Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):581-93 - PubMed
  53. Cell Immunol. 1987 Oct 1;109(1):89-96 - PubMed
  54. Trends Microbiol. 1996 Oct;4(10):394-400 - PubMed
  55. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7508-13 - PubMed
  56. Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):569-79 - PubMed
  57. J Virol. 1996 Oct;70(10):6775-80 - PubMed
  58. Immunity. 1998 Mar;8(3):363-72 - PubMed
  59. Mol Med Today. 2000 Dec;6(12):488-90 - PubMed
  60. J Exp Med. 1999 Oct 4;190(7):1013-24 - PubMed
  61. Mech Ageing Dev. 2003 Apr;124(4):477-85 - PubMed
  62. Crit Rev Immunol. 1996;16(4):381-421 - PubMed
  63. J Virol. 1993 Sep;67(9):5247-52 - PubMed
  64. J Immunol. 2007 Jul 1;179(1):141-53 - PubMed
  65. Exp Gerontol. 2008 Jan;43(1):34-8 - PubMed
  66. J Lab Clin Med. 1978 Nov;92(5):822-8 - PubMed
  67. J Immunol. 2002 Apr 15;168(8):3958-64 - PubMed
  68. Immunol Rev. 2005 Jun;205:220-8 - PubMed
  69. Immunol Res. 2005;32(1-3):293-315 - PubMed
  70. Adv Virus Res. 1999;52:139-232 - PubMed
  71. J Immunol. 2005 Sep 1;175(5):3225-34 - PubMed
  72. Yale J Biol Med. 1987 Jul-Aug;60(4):321-32 - PubMed
  73. Eur J Immunol. 1988 Feb;18(2):313-6 - PubMed
  74. Immunology. 1989 Nov;68(3):312-8 - PubMed
  75. J Immunol. 1993 Jan 15;150(2):543-9 - PubMed
  76. J Virol. 2002 Jul;76(14):7125-32 - PubMed
  77. J Exp Med. 1996 Sep 1;184(3):863-71 - PubMed
  78. Arch Dermatol. 1997 Jul;133(7):867-71 - PubMed
  79. Eur J Immunol. 2002 Jun;32(6):1567-73 - PubMed
  80. J Immunol. 2007 Feb 1;178(3):1692-701 - PubMed
  81. Nature. 2008 Sep 25;455(7212):532-6 - PubMed
  82. J Virol. 2000 Dec;74(24):11495-503 - PubMed
  83. Pediatr Nephrol. 2004 Apr;19(4):369-77 - PubMed
  84. Curr Opin Immunol. 2004 Aug;16(4):443-50 - PubMed
  85. Exp Gerontol. 2007 Jun;42(6):563-70 - PubMed
  86. J Infect Dis. 1977 Mar;135(3):374-9 - PubMed
  87. Cell Immunol. 1991 Mar;133(1):72-83 - PubMed
  88. Science. 1996 Jul 5;273(5271):70-4 - PubMed
  89. Immunol Rev. 1997 Dec;160:63-77 - PubMed

Publication Types